March 16, 2014 Kymab, a monoclonal antibody biopharmaceutical company founded on research from the Wellcome Trust Sanger Institute, announced today the publication in Nature Biotechnology of a paper describing its breakthrough therapeutic antibody discovery technology, Kymouse™. Scientists at Kymab have engineered a mouse with the full set of genes encoding the human antibody repertoire, calling this new technology Kymouse™. They have demonstrated that …
